PortalPublikationenPrechemotherapy Not Preorchiectomy Serum Tumor Markers Accur...

Prechemotherapy Not Preorchiectomy Serum Tumor Markers Accurately Identify International Germ Cell Cancer Collaborative Group Prognostic Groups in Nonseminoma

Standard

Prechemotherapy Not Preorchiectomy Serum Tumor Markers Accurately Identify International Germ Cell Cancer Collaborative Group Prognostic Groups in Nonseminoma. / Fankhauser, Christian D; Jandari, Abolghassem; Collette, Laurence; Tandstad, Torgrim; Jiang, Di Maria; De Giorgi, Ugo; Sweeney, Christopher; Terbuch, Angelika; Chovanec, Michal; Huddart, Robert; Bokemeyer, Carsten; Beyer, Jörg; Gillessen, Silke.

in: EUR UROL OPEN SCI, Jahrgang 56, 10.2023, S. 25-28.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › Kurzpublikation › Forschung › Begutachtung

Harvard

Fankhauser, CD, Jandari, A, Collette, L, Tandstad, T, Jiang, DM, De Giorgi, U, Sweeney, C, Terbuch, A, Chovanec, M, Huddart, R, Bokemeyer, C, Beyer, J & Gillessen, S 2023, 'Prechemotherapy Not Preorchiectomy Serum Tumor Markers Accurately Identify International Germ Cell Cancer Collaborative Group Prognostic Groups in Nonseminoma', EUR UROL OPEN SCI, Jg. 56, S. 25-28. https://doi.org/10.1016/j.euros.2023.08.008

APA

Fankhauser, C. D., Jandari, A., Collette, L., Tandstad, T., Jiang, D. M., De Giorgi, U., Sweeney, C., Terbuch, A., Chovanec, M., Huddart, R., Bokemeyer, C., Beyer, J., & Gillessen, S. (2023). Prechemotherapy Not Preorchiectomy Serum Tumor Markers Accurately Identify International Germ Cell Cancer Collaborative Group Prognostic Groups in Nonseminoma. EUR UROL OPEN SCI, 56, 25-28. https://doi.org/10.1016/j.euros.2023.08.008

Vancouver

Fankhauser CD, Jandari A, Collette L, Tandstad T, Jiang DM, De Giorgi U et al. Prechemotherapy Not Preorchiectomy Serum Tumor Markers Accurately Identify International Germ Cell Cancer Collaborative Group Prognostic Groups in Nonseminoma. EUR UROL OPEN SCI. 2023 Okt;56:25-28. https://doi.org/10.1016/j.euros.2023.08.008

Bibtex

@article{1ef9efc6c8064a98a319e2c0a9299af2,
title = "Prechemotherapy Not Preorchiectomy Serum Tumor Markers Accurately Identify International Germ Cell Cancer Collaborative Group Prognostic Groups in Nonseminoma",
abstract = "UNLABELLED: Levels of the serum tumor markers (STMs) α-fetoprotein, human chorionic gonadotropin, and lactate dehydrogenase are used in staging classification for metastatic germ-cell cancers and support decisions on the intensity of first-line treatment for patients with nonseminoma. Use of preorchiectomy instead of prechemotherapy STM levels can lead to inadequate classification. We identified 744 men with metastatic gonadal nonseminoma in the International Germ-Cell Cancer Collaborative Group (IGCCCG) Update Consortium database who had preorchiectomy and prechemotherapy STM levels available. Of these, 22% would have had inadequate IGCCCG prognostic group classification if preorchiectomy levels had been used, which would have resulted in overtreatment of 16% and undertreatment of 6% of men. These findings suggest that use of preorchiectomy instead of prechemotherapy STM results may lead to incorrect IGCCCG classification, which could compromise treatment success or expose patients to unnecessary toxicity.PATIENT SUMMARY: For men with testicular cancer, levels of tumor markers in their blood are used when making decisions on chemotherapy intensity. Use of test results for samples taken before removal of the cancer-bearing testicle instead of immediately before chemotherapy can lead to inadequate treatment recommendations.",
author = "Fankhauser, {Christian D} and Abolghassem Jandari and Laurence Collette and Torgrim Tandstad and Jiang, {Di Maria} and {De Giorgi}, Ugo and Christopher Sweeney and Angelika Terbuch and Michal Chovanec and Robert Huddart and Carsten Bokemeyer and J{\"o}rg Beyer and Silke Gillessen",
note = "{\textcopyright} 2023 Published by Elsevier B.V. on behalf of European Association of Urology.",
year = "2023",
month = oct,
doi = "10.1016/j.euros.2023.08.008",
language = "English",
volume = "56",
pages = "25--28",
journal = "EUR UROL OPEN SCI",
issn = "2666-1691",
publisher = "Elsevier BV",

}

RIS

TY - JOUR

T1 - Prechemotherapy Not Preorchiectomy Serum Tumor Markers Accurately Identify International Germ Cell Cancer Collaborative Group Prognostic Groups in Nonseminoma

AU - Fankhauser, Christian D

AU - Jandari, Abolghassem

AU - Collette, Laurence

AU - Tandstad, Torgrim

AU - Jiang, Di Maria

AU - De Giorgi, Ugo

AU - Sweeney, Christopher

AU - Terbuch, Angelika

AU - Chovanec, Michal

AU - Huddart, Robert

AU - Bokemeyer, Carsten

AU - Beyer, Jörg

AU - Gillessen, Silke

N1 - © 2023 Published by Elsevier B.V. on behalf of European Association of Urology.

PY - 2023/10

Y1 - 2023/10

N2 - UNLABELLED: Levels of the serum tumor markers (STMs) α-fetoprotein, human chorionic gonadotropin, and lactate dehydrogenase are used in staging classification for metastatic germ-cell cancers and support decisions on the intensity of first-line treatment for patients with nonseminoma. Use of preorchiectomy instead of prechemotherapy STM levels can lead to inadequate classification. We identified 744 men with metastatic gonadal nonseminoma in the International Germ-Cell Cancer Collaborative Group (IGCCCG) Update Consortium database who had preorchiectomy and prechemotherapy STM levels available. Of these, 22% would have had inadequate IGCCCG prognostic group classification if preorchiectomy levels had been used, which would have resulted in overtreatment of 16% and undertreatment of 6% of men. These findings suggest that use of preorchiectomy instead of prechemotherapy STM results may lead to incorrect IGCCCG classification, which could compromise treatment success or expose patients to unnecessary toxicity.PATIENT SUMMARY: For men with testicular cancer, levels of tumor markers in their blood are used when making decisions on chemotherapy intensity. Use of test results for samples taken before removal of the cancer-bearing testicle instead of immediately before chemotherapy can lead to inadequate treatment recommendations.

AB - UNLABELLED: Levels of the serum tumor markers (STMs) α-fetoprotein, human chorionic gonadotropin, and lactate dehydrogenase are used in staging classification for metastatic germ-cell cancers and support decisions on the intensity of first-line treatment for patients with nonseminoma. Use of preorchiectomy instead of prechemotherapy STM levels can lead to inadequate classification. We identified 744 men with metastatic gonadal nonseminoma in the International Germ-Cell Cancer Collaborative Group (IGCCCG) Update Consortium database who had preorchiectomy and prechemotherapy STM levels available. Of these, 22% would have had inadequate IGCCCG prognostic group classification if preorchiectomy levels had been used, which would have resulted in overtreatment of 16% and undertreatment of 6% of men. These findings suggest that use of preorchiectomy instead of prechemotherapy STM results may lead to incorrect IGCCCG classification, which could compromise treatment success or expose patients to unnecessary toxicity.PATIENT SUMMARY: For men with testicular cancer, levels of tumor markers in their blood are used when making decisions on chemotherapy intensity. Use of test results for samples taken before removal of the cancer-bearing testicle instead of immediately before chemotherapy can lead to inadequate treatment recommendations.

U2 - 10.1016/j.euros.2023.08.008

DO - 10.1016/j.euros.2023.08.008

M3 - Short publication

C2 - 37711670

VL - 56

SP - 25

EP - 28

JO - EUR UROL OPEN SCI

JF - EUR UROL OPEN SCI

SN - 2666-1691

ER -